XCancer

Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT

Description:

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Sponsor:

Jonsson Comprehensive Cancer Center (UCLA)

Phase:

N/A

Contacts:

Soosan Roodbari

sroodbari@mednet.ucla.edu

310 794-1596

Government Study Link:

NCT02902757 - Click here to see study on

ClinicalTrials.gov

Isotope(s):
Target(s):
Inclusion
  • Intention to start therapy
  • Patients with histologically proven high grade glioma
Exclusion
  • Inability to give written consent
  • Severe psychiatric illness
  • Breast feeding / pregnancy

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...